Kura Oncology Inc. and Kyowa Kirin Co., Ltd. have announced new data from the ongoing KOMET-007 Phase 1a/1b clinical trial evaluating KOMZIFTI (ziftomenib) in combination with venetoclax and azacitidine for the treatment of acute myeloid leukemia (AML) with NPM1 mutations or KMT2A rearrangements. The results, which demonstrate a favorable safety profile and encouraging antileukemic activity, were presented in two oral presentations at the 67th Annual Meeting of the American Society of Hematology (ASH 2025). Data highlights include an 86% composite complete remission rate and a 73% complete remission rate in newly diagnosed NPM1-mutant AML patients, as well as promising response rates in the relapsed/refractory setting. According to the companies, the triplet combination was well tolerated, with no increased toxicity observed beyond that expected with venetoclax and azacitidine alone. Slides from the presentations and a webcast replay are available on Kura Oncology's website.